Moleculin Biotech, Inc. Made Headway
Fri, Feb 14, 2025 at 07:31 PM
Moleculin Biotech, Inc. (MBRX:NASDAQ) rocketted at $2.18, a gain of 71.7%. On Fri, Feb 14, 2025, MBRX:NASDAQ touched a New 2-Week High of $2.18. The stock appeared on our News Catalysts scanner on Fri, Feb 14, 2025 at 11:36 AM in the 'EARNINGS' category. From Fri, Jan 31, 2025, the stock recorded 20.00% Up Days and 18.18% Green Days
The stock spiked on Thu, Feb 13, 2025 at $3.65 with a volume of 100M+.
About Moleculin Biotech, Inc. (MBRX:NASDAQ)
Moleculin Biotech Inc is a preclinical stage pharmaceutical company. The company is engaged in the development of anti-cancer drug candidates. Its drug development technologies include liposomal Annamycin, WP1122 and WP1066.
Top 10 Gainers:
- JetAI Inc Com (JTAI:NASDAQ), 133.72%
- SRM Entertainment Inc. (SRM:NASDAQ), 95.53%
- WeRide Inc. (WRD:NASDAQ), 83.46%
- INLIF LIMITED (INLF:NASDAQ), 81.24%
- Moleculin Biotech, Inc. (MBRX:NASDAQ), 71.65%
- Sacks Parente Golf Inc. (SPGC:NASDAQ), 49.14%
- Allogene Therapeutics, Inc. (ALLO:NASDAQ), 44.68%
- Latch Inc. (LTCH:NASDAQ), 42.86%
- Fitell Corporation (FTEL:NASDAQ), 35.79%
- XChange TEC.INC American Depositary Shares (XHG:NASDAQ), 35.36%